DANIEL HARRISON
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology BALTIMORE, MD NPI 1578733242
Browse related groups: Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology MD TG THERAPEUTICS, INC. All categories
General Payments — all program years on this page
$32,217.62
- Category: General Payments
- Program years: PY2018–2024
- Record count: 60
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $1,989.00 across 7 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $1,688.00 | 1 |
| Food and Beverage | $301.00 | 6 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| TG THERAPEUTICS, INC. | $1,688.00 | 1 |
| GENZYME CORPORATION | $99.47 | 1 |
| Genentech USA, Inc. | $95.67 | 1 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $91.40 | 3 |
| Amgen Inc. | $14.46 | 1 |
By program year
Records — PY2024 (7)
| Record ID | Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Source |
|---|---|---|---|---|---|---|---|
| 1086908461 | Novartis Pharmaceuticals Corporation | $29.01 | 04/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1086908463 | Novartis Pharmaceuticals Corporation | $31.30 | 09/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1086908465 | Novartis Pharmaceuticals Corporation | $31.09 | 11/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1111595298 | Amgen Inc. | $14.46 | 01/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1132993838 | Genentech USA, Inc. | $95.67 | 09/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1136874809 | TG Therapeutics, Inc. | $1,688.00 | 09/25/2024 | Consulting Fee | Undisputed | 01/23/2026 | View at CMS |
| 1139831078 | GENZYME CORPORATION | $99.47 | 02/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.